{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:09:50Z","timestamp":1767006590973},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,14]]},"DOI":"10.7759\/cureus.17961","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T13:23:56Z","timestamp":1631625836000},"source":"Crossref","is-referenced-by-count":12,"title":["Neuromyelitis Optica in a Healthy Female After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine"],"prefix":"10.7759","author":[{"given":"Priscilla","family":"Fujikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhan A","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michalla","family":"Braford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kashyap","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Madey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms131012970","article-title":"Molecular pathogenesis of neuromyelitis optica","volume":"13","author":"Bukhari W","year":"2012","unstructured":"Bukhari W, Barnett MH, Prain K, Broadley SA. Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci. 2012, 13:12970-93. 10.3390\/ijms131012970","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda S","year":"2019","unstructured":"Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019, 19:169-76. 10.7861\/clinmedicine.19-2-169","journal-title":"Clin Med (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor JY","year":"2020","unstructured":"Hor JY, Asgari N, Nakashima I, et al.. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020, 11:501. 10.3389\/fneur.2020.00501","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P1.2-003","article-title":"Systematic review investigating relationship between neuromyelitis optica spectrum disorder (NMOSD) and vaccination","volume":"92","author":"Vanood A","year":"2019","unstructured":"Vanood A, Wingerchuk D. Systematic review investigating relationship between neuromyelitis optica spectrum disorder (NMOSD) and vaccination. Neurology. 2019, 92:P1.2-003.","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.05.003","article-title":"Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Mealy MA","year":"2018","unstructured":"Mealy MA, Cook LJ, Pache F, et al.. Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018, 23:78-82. 10.1016\/j.msard.2018.05.003","journal-title":"Mult Scler Relat Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/sni.sni_224_18","article-title":"Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico","volume":"9","author":"Zarei S","year":"2018","unstructured":"Zarei S, Eggert J, Franqui-Dominguez L, et al.. Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico. Surg Neurol Int. 2018, 9:242. 10.4103\/sni.sni_224_18","journal-title":"Surg Neurol Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk DM","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al.. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015, 85:177-89. 10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim SM","year":"2017","unstructured":"Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, Fujihara K. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2017, 10:265-89. 10.1177\/1756285617709723","journal-title":"Ther Adv Neurol Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler RA","year":"2016","unstructured":"Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol. 2016, 18:2. 10.1007\/s11940-015-0387-9","journal-title":"Curr Treat Options Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10235-5","article-title":"Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder","author":"Holm\u00f8y T","year":"2020","unstructured":"Holm\u00f8y T, H\u00f8glund RA, Illes Z, Myhr KM, Torkildsen \u00d8. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol. 2020, 10.1007\/s00415-020-10235-5","journal-title":"J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102538","article-title":"Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects","volume":"46","author":"Brod SA","year":"2020","unstructured":"Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord. 2020, 46:102538. 10.1016\/j.msard.2020.102538","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: a review in neuromyelitis optica spectrum disorder","volume":"80","author":"Frampton JE","year":"2020","unstructured":"Frampton JE. Eculizumab: a review in neuromyelitis optica spectrum disorder. Drugs. 2020, 80:719-27. 10.1007\/s40265-020-01297-w","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/66554-neuromyelitis-optica-in-a-healthy-female-after-severe-acute-respiratory-syndrome-coronavirus-2-mrna-1273-vaccine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T09:52:06Z","timestamp":1725789126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/66554-neuromyelitis-optica-in-a-healthy-female-after-severe-acute-respiratory-syndrome-coronavirus-2-mrna-1273-vaccine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.17961","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2021,9,14]]}}}